1. Search Result
Search Result
Results for "

hnrnp

" in MedChemExpress (MCE) Product Catalog:

14

Inhibitors & Agonists

1

Natural
Products

13

Recombinant Proteins

32

Antibodies

4

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N6796
    Manumycin A
    2 Publications Verification

    Antibiotic Exosomes Farnesyl Transferase Ras Apoptosis Phospholipase TNF Receptor Atg8/LC3 Infection Inflammation/Immunology Cancer
    Manumycin A is a polyketide antibiotic and an inhibitor of thioredoxin reductase 1 (TrxR-1). Manumycin A can inhibit the growth of breast cancer cells and exert its anti-tumor activity through LC3. Manumycin A can downregulate the release of pro-inflammatory cytokines in human monocytes stimulated by TNF α, and has potential anti-inflammatory activity. Manumycin A can inhibit the Ras/Raf/ERK1/2 signaling and hnRNP H1 in castration resistant prostate cancer cells to suppress exosome biogenesis and secretion .
    Manumycin A
  • HY-126076A

    DNA/RNA Synthesis Cancer
    VPC-80051 is an inhibitor of hnRNP A1 splicing activity. VPC-80051 directly interacts with hnRNP A1 RBD and reduces AR-V7 messenger levels in 22Rv1 CRPC cell line. VPC-80051 can be used in prostate cancer research .
    VPC-80051
  • HY-126076
    VPC-80051 racemate
    1 Publications Verification

    Drug Isomer DNA/RNA Synthesis Others
    VPC-80051 racemate is a racemate of VPC-80051. VPC-80051 is a prototype inhibitor of the hnRNP A1 splicing factor .
    VPC-80051 racemate
  • HY-170964

    DNA/RNA Synthesis TGF-β Receptor Cancer
    HPH-15 is an anti-migration compound that inhibits cell migration by binding to hnRNP U or suppressing TGF-β signaling. In addition, HPH-15 can also inhibit epithelial-mesenchymal transition (EMT). HPH-15 holds promise for research in the fields of anti-tumor metastasis and anti-fibrosis .
    HPH-15
  • HY-141878

    RIBOTAC DNA/RNA Synthesis Neurological Disease
    di-Ellipticine-RIBOTAC is a RNase recruiting chimera (RIBOTAC) degrader, capable of specifically binding and degrading expanded G4C2 RNA repeat (r(G4C2) exp). di-Ellipticine-RIBOTAC selectively binds the three-dimensional (3D) structure formed by r(G4C2) exp and that recruits an endogenous ribonuclease (RNase) to cleave r(G4C2) exp. di-Ellipticine-RIBOTAC selectively degrades the mutant chromosome 9 open reading frame 72 (C9orf72) allele and reduces quantities of toxic dipeptide repeat proteins (DPRs) translated from r(G4C2) exp. di-Ellipticine-RIBOTAC significantly improves the pathological phenotype of amyotrophic lateral sclerosis/ frontotemporal dementia (c9ALS/FTD) in cells and mouse models. di-Ellipticine-RIBOTAC can be used for the study of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) .
    di-Ellipticine-RIBOTAC
  • HY-155050

    Apoptosis Histone Methyltransferase Cancer
    PRMT5-IN-31 (Compound 3m) is a selective PRMT5 inhibitor (IC50: 0.31 μM). PRMT5-IN-31 up-regulates hnRNP E1 protein level. PRMT5-IN-31 occupies the substrate site of PRMT5 and forms essential interactions with amino acid residues. PRMT5-IN-31 has antiproliferative effects against A549 cells by inducing apoptosis and inhibiting cell migration. PRMT5-IN-31 has high metabolic stability on human liver microsomes (T1/2: 132.4 min) .
    PRMT5-IN-31
  • HY-160049

    Nucleoside Antimetabolite/Analog Biochemical Assay Reagents Cancer
    BC15 aptamer sodium is an ssDNA aptamer targeting the intracellular protein hnRNP A1, which is highly expressed in cancerous liver tissue. BC15 aptamer sodium specifically recognizes breast cancer cells and can be used to detect cancer cells in other pathological types of breast cancer tissue .
    BC15 aptamer sodium
  • HY-RS06265

    Small Interfering RNA (siRNA) Others

    HNRNPC Human Pre-designed siRNA Set A contains three designed siRNAs for HNRNPC gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    HNRNPC Human Pre-designed siRNA Set A
    HNRNPC Human Pre-designed siRNA Set A
  • HY-RS06268

    Small Interfering RNA (siRNA) Others

    HNRNPDL Human Pre-designed siRNA Set A contains three designed siRNAs for HNRNPDL gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    HNRNPDL Human Pre-designed siRNA Set A
    HNRNPDL Human Pre-designed siRNA Set A
  • HY-155051

    Apoptosis Histone Methyltransferase Cancer
    Antiproliferative agent-25 (Compound 3s4) is a selective PRMT5 inhibitor (IC50: 0.11 μM). Antiproliferative agent-25 up-regulates hnRNP E1 protein level. Antiproliferative agent-25 forms H-bond interactions with SAM and E444 residue of PRMT5. Antiproliferative agent-25 has antiproliferative effects against A549 cells by inducing apoptosis and inhibiting cell migration. Antiproliferative agent-25 has high clearances with T1/2 of only 21.8 and 4.7 min in human and rat liver microsomes .
    Antiproliferative agent-25
  • HY-141878A

    RIBOTAC DNA/RNA Synthesis Neurological Disease
    di-Ellipticine-RIBOTAC TFA is a RNase recruiting chimera (RIBOTAC) degrader, capable of specifically binding and degrading expanded G4C2 RNA repeat (r(G4C2) exp). di-Ellipticine-RIBOTAC TFA selectively binds the three-dimensional (3D) structure formed by r(G4C2) exp and that recruits an endogenous ribonuclease (RNase) to cleave r(G4C2) exp. di-Ellipticine-RIBOTAC TFA selectively degrades the mutant chromosome 9 open reading frame 72 (C9orf72) allele and reduces quantities of toxic dipeptide repeat proteins (DPRs) translated from r(G4C2) exp. di-Ellipticine-RIBOTAC TFA significantly improves the pathological phenotype of amyotrophic lateral sclerosis/ frontotemporal dementia (c9ALS/FTD) in cells and mouse models. di-Ellipticine-RIBOTAC TFA can be used for the study of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) .
    di-Ellipticine-RIBOTAC TFA
  • HY-182546

    DNA/RNA Synthesis Cancer
    Anticancer agent 312 is a heterogeneous nuclear ribonucleoprotein A18 (hnRNP A18) inhibitor with an IC50 of 2.9 μM. Anticancer agent 312 binds to the RNA recognition motif of hnRNP A18 and blocks its binding to homologous RNA transcripts. Anticancer agent 312 acts as a protein synthesis inhibitor by blocking hnRNP A18-mediated mRNA translation. Anticancer agent 312 is applicable to research on cancers such as melanoma .
    Anticancer agent 312
  • HY-182514

    HIV hnRNP Infection Cancer
    BMMP is an anti-HIV-1 agent and hnRNP M modulator. BMMP modulates hnRNP M function to suppress CD44 mRNA expression. BMMP induces abnormal uncoating of the HIV viral core at the post-entry step. BMMP suppresses migration of TGF-β-stimulated lung carcinoma cells. BMMP suppresses HIV-1 reverse transcription and replication without inhibiting virion release. BMMP exerts anti-HIV-1 activity via a mechanism distinct from CA protein-binding heterocyclic compounds. BMMP can be used for the research of human immunodeficiency virus infection and non-small cell lung cancer .
    BMMP
  • HY-RS24584

    Small Interfering RNA (siRNA) Others

    Hnrnpa2b1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Hnrnpa2b1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Hnrnpa2b1 Rat Pre-designed siRNA Set A
    Hnrnpa2b1 Rat Pre-designed siRNA Set A

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: